Common factors such as education, ethnicity, income, and marital status do not appear to be risk factors for the development of MDD. Instead, MDD often emerges subsequent to a significant ...

In a recent study, transcranial magnetic stimulation was found to be more effective than switching to a new medication for ...

A mental health professional familiar with cognitive remediation would be the best guide for group treatment. Do you live with major depressive disorder? Learn about the resources and protections ...

Major depressive disorder (MDD) is a chronic and recurrent ... of such MDD patients remit following adequate antidepressant treatment, while most MDD patients suffer from significant core ...

About one-third of U.S. adults without diabetes who are eligible for weight loss treatment with glucagon ... The diagnosis of major depressive disorder is based on the patient's self-reported ...

Sleep problems may be one of the first symptoms of major depressive disorder -- a serious ... the sooner you can get the treatment you need to get you back on your feet. Talk to your doctor ...

Lysergic acid diethylamide is under clinical development by Mind Medicine MindMed and currently in Phase II for Major Depressive Disorder.

In past trials, ketamine intravenous treatment has shown promise, with 64% of depression patients in trials experiencing ...

Major depressive disorder is a debilitating ... firm bright light therapy as an efficient adjunctive treatment for non-seasonal depressive disorders,” the researchers wrote in their study ...

The proportion of people with major depressive disorder receiving minimally adequate treatment by country, 2021. Credit: The Lancet Psychiatry (2024). DOI: 10.1016/S2215-0366(24)00317-1 ...

its Phase 3 pivotal program evaluating the efficacy and safety of CYB003 for the adjunctive treatment of Major Depressive Disorder (“MDD”). The program name, PARADIGM, represents the Company's ...